Browsing Tag
Merck & Co. Inc.
3 posts
Moderna (MRNA) falls 18% despite melanoma win: Can an $81bn valuation hold?
Moderna shares plunged 17.57% despite positive Phase 3 melanoma data from its personalised mRNA cancer therapy developed with Merck. With an approximately $81 billion market valuation, continued operating losses and a commercial opportunity extending well beyond melanoma, the central question is how much future oncology success investors have already priced in.
Immutep shares surge 27% as efti strategy narrows after TACTI-004 failure
Immutep Limited is narrowing eftilagimod alfa development to two oncology settings and returning to 200-litre manufacturing after finding structural differences between the material used in failed Phase III TACTI-004 and earlier successful studies.
Cipla bets on Qilu’s Keytruda biosimilar as $31.7bn oncology franchise nears expiry
Cipla has secured exclusive U.S. commercialization rights to Qilu Pharmaceutical’s Phase 3 pembrolizumab biosimilar, positioning the Indian drugmaker for competition around Merck & Co.’s $31.7 billion Keytruda franchise.